This guide explores whether the physical location of a CDMO becomes part of selection criteria and compares one-site CDMOs with multi-site and global CDMOs for small to medium-sized biotechs.
Benefits of a One-Site Model
Co-located teams reduce handoffs, speed communication and give sponsors a single point of contact for development and manufacturing.
Multi-Site and Global Considerations
Larger networks offer scale and geographic reach but can introduce complexity in coordination and transfer.
Choosing the Right Fit
Program complexity, timelines and sponsor size should guide the decision between one-site and multi-site partners.
About This White Paper
This white paper is published by Upperton and curated by Biotechnology Media Insights, a trusted source for pharmaceutical and biotechnology research, technical guides and industry analysis.